Exit / M&A
Beaten Zone Team Expands
Defence-focused VC firm Beaten Zone Venture Partners adds two people: ex-Army general Mick Ryan as advisor, and Peta Ellis rejoining Steve Baxter's team alongside existing staff.
Company
Johns Hopkins University
Baltimore
Funding history
Investors
Every investor coverage indicates participated in a round Johns Hopkins University raised.
What Johns Hopkins University bought
Companies Johns Hopkins University acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| Dr Brian Hearing | Scientist (former) | @AuManufacturing |
Coverage
Stories naming Johns Hopkins University. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Unnamed stage
$15m
The biotech startup behind the petri dish of brain cells that played Pong just raised $15 million
Melbourne synthetic biology company Cortical Labs has secured US$10 million (A$15 million), led by Horizons Ventures with four co-investors, to advance its brain-cell computing platform commercially and meet pre-orders.
Also TechCrunch Venture·Forbes Australia·SmartCompany·Forbes Australia·Crunchbase News·Crunchbase News
News
Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.
Key hire
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Key hire
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.